Testosterone Protects Against Gynecomastia: How T Silences Estrogen Signaling in Mammary Tissue

[Nelson Vergel]

New Single-Cell Research Reveals Why High Testosterone Levels May Shield Against Hormone-Driven Breast Cancer - and What It Means for Men on TRT
Curated By Nelson Vergel | ExcelMale.com | Updated April 2026

Key Takeaways • Testosterone actively suppresses estrogen signaling in breast tissue - even when estradiol levels in the blood remain normal. The hormone doesn't just compete; it effectively blinds breast cells to estrogen's growth-promoting signals. • Single-cell RNA sequencing from a January 2026 preprint (Phong et al.) shows that testosterone replacement therapy shuts down key growth genes like PTHLH, AREG, and WNT4 in hormone receptor-positive breast cells - the exact cell type where most breast cancers originate. • The "aromatase concern" - the fear that testosterone converts to estrogen and fuels breast growth - is not supported by current evidence. Even with physiological estradiol present, testosterone overrides estrogen's downstream effects at the tissue level. • For men on TRT, this research provides reassurance: testosterone's anti-estrogenic action in breast tissue helps explain why gynecomastia is uncommon at physiological doses, and underscores why crashing estradiol with aromatase inhibitors may be unnecessary and harmful. • The data also carry implications for women's health: testosterone pellet therapy has been associated with reduced breast cancer incidence in postmenopausal women, and emerging research is exploring androgen therapy as a potential strategy to prevent ER-positive breast cancer.

Introduction: Rethinking What Testosterone Does to Breast Tissue​

What comes to mind when you hear "testosterone" and "breast tissue" in the same sentence? If you're like many men on TRT, your first thought is probably gynecomastia - the fear that excess testosterone will convert to estrogen and cause unwanted breast growth. It's a worry that has driven countless men to request aromatase inhibitors the moment they start therapy. But what if the relationship between testosterone and breast tissue is fundamentally different from what most people assume?
A growing body of molecular research - including two landmark single-cell sequencing studies from 2023 and early 2026 - is turning that assumption on its head. Rather than fueling breast growth through estrogen conversion, testosterone appears to function as a powerful anti-estrogen in mammary tissue. It doesn't just passively coexist with estradiol. It actively silences the molecular machinery that estrogen uses to stimulate cell growth. The breast tissue of individuals receiving high-dose testosterone looks, at the molecular level, nothing like tissue in a high-estrogen environment. Instead, it resembles tissue in a state of deep hormonal quiet - what researchers are calling "transcriptomic amenorrhea."
This article breaks down the science behind testosterone's protective role in breast tissue, what it means for men managing estrogen on TRT, and how the same biology is opening new doors in breast cancer prevention for women. The evidence comes from cutting-edge single-cell RNA sequencing - technology that allows researchers to examine what each individual cell is doing, rather than averaging signals across an entire tissue sample. For the ExcelMale community, where managing the testosterone-to-estradiol balance is a daily conversation, these findings provide a new, evidence-based perspective.

The Study That Changed the Conversation​

In January 2026, a research team led by Kiet Phong, Siyou Song, and Zev Gartner at UCSF posted a preprint on bioRxiv that represents one of the most granular looks yet at how testosterone affects healthy breast tissue. The study compared breast tissue from seven transgender men who had been receiving testosterone replacement therapy for an average of 18.4 months with tissue from seven cisgender women matched for age and BMI.
What made this study stand apart from earlier work is the technology: single-cell RNA sequencing (scRNA-seq). Unlike traditional "bulk" RNA analysis, which blends the signals from every cell type together, scRNA-seq isolates each cell and reads its gene expression individually. This distinction matters enormously in breast tissue. Under testosterone, the breast undergoes significant structural changes - lobular atrophy, expansion of fibrous stroma, and a shift in the proportions of different cell types. If you analyze all those cells together, the stromal signals drown out what the epithelial cells - the cells where breast cancer actually starts - are doing. Single-cell resolution cuts through that noise.
This 2026 preprint built directly on a 2023 study published in Cell Genomics by Raths, Karimzadeh, Knott, and colleagues at Cedars-Sinai Medical Center. That earlier paper combined single-nucleus RNA sequencing, chromatin accessibility profiling (snATAC-seq), and spatial protein imaging (CODEX) to map how androgen therapy reshapes the entire cellular landscape of the breast. Together, these two studies form a remarkably consistent picture.

The Sentinel Cells: Where Testosterone Strikes First​

Not every cell in the breast responds to testosterone in the same way. Both research teams used computational tools - including the Augur cell-type prioritization algorithm - to identify which cells were most dramatically transformed by androgen exposure. The answer was clear and consistent: hormone receptor-positive (HR+) luminal epithelial cells are testosterone's primary target.
Think of HR+ luminal cells as the breast's command center. They carry the molecular equipment to sense both estrogen and testosterone, and they coordinate the behavior of surrounding cells through paracrine signaling - chemical messages broadcast to neighboring cells. When estrogen activates these cells during the normal menstrual cycle, they release growth factors that drive ductal elongation, side-branching, and tissue expansion. In short, these are the cells responsible for estrogen-driven breast development - and they're also the cells where approximately 70-80% of all breast cancers originate.
What makes HR+ luminal cells uniquely sensitive to testosterone is their receptor profile. The androgen receptor (AR) is expressed in an even higher percentage of these cells than the estrogen receptor alpha (ESR1). So when testosterone levels rise to male physiological ranges (234-758 ng/dL in the TRT cohort), these cells don't just sense the change - they pivot dramatically. Their entire gene expression program shifts away from estrogen-driven growth and toward a state of hormonal silence.

The Estradiol Paradox: Normal Blood Levels, Silent Tissue​

Here's the finding that surprised researchers most: the transgender men on TRT still had measurable estradiol in their blood. Their serum E2 levels ranged from 12-87 pg/mL - overlapping considerably with the control group. The difference between groups was not statistically significant. In other words, estradiol was physically present and circulating at physiologically meaningful levels.
Yet inside the breast tissue, it was as if estrogen didn't exist.
Researchers quantified this by measuring "luteal phase gene signatures" - a set of genes that normally ramp up during the high-hormone phase of the menstrual cycle. In control subjects, several women showed strong luteal signatures consistent with active estrogen and progesterone signaling. In every single TRT subject, these signatures were absent. The tissue had entered what the research team described as "transcriptomic amenorrhea" - the molecular equivalent of menopause-level hormonal quiet, even though systemic estradiol was still present.
Two mechanisms drive this disconnection. First, TRT induces anovulation (progesterone levels were uniformly below 0.1 ng/mL in the TRT group, versus up to 7.8 ng/mL in controls), which eliminates the hormonal cycling that periodically drives breast tissue into a high-proliferation state. Second - and more importantly - testosterone directly antagonizes estrogen receptor signaling at the cellular level, preventing estradiol from activating its downstream growth programs.
For men on TRT, this concept should feel familiar. You already know that testosterone and estradiol coexist in your body. The question is whether that estradiol is actually doing damage - and these data suggest that when testosterone is sufficiently high, estrogen's voice in breast tissue gets effectively muted.

The Molecular Hit List: Which Growth Signals Does Testosterone Silence?​

When testosterone takes control of HR+ luminal cells, it doesn't just turn down a few genes. It systematically dismantles the paracrine signaling network that estrogen uses to drive breast tissue growth. Here are the most clinically significant targets:

PTHLH (Parathyroid Hormone-Like Hormone)​

This was the single most suppressed gene in the entire TRT cohort, with a staggering log2 fold change of -6.81. To put that in plain language, PTHLH expression in TRT subjects was approximately 112 times lower than in controls. PTHLH plays dual roles: it's essential for normal mammary development, but it's also strongly implicated in breast cancer bone metastasis. Its profound suppression suggests that testosterone doesn't just prevent growth - it may reduce the metastatic potential of the tissue environment.

AREG (Amphiregulin) and EREG (Epiregulin)​

These are ligands for the epidermal growth factor receptor (EGFR). Amphiregulin is considered the essential mediator of estrogen-driven ductal elongation in the breast. When you suppress AREG and EREG, you cut the primary growth signal that estrogen broadcasts to surrounding tissue. Without these signals, the ductal expansion that characterizes active breast development simply doesn't happen.

WNT4 and RANKL (TNFSF11)​

WNT4 and RANKL are progesterone-responsive signaling molecules that drive side-branching of mammary ducts and regulate mammary stem cell activity. Their suppression (log2 fold changes of -3.31 and -4.47, respectively) effectively prevents the tissue remodeling that occurs during the luteal phase of the menstrual cycle. This is significant because repeated luteal-phase cycling - with its recurrent bursts of proliferative signaling - is itself a risk factor for breast cancer.

Gene​	Function​	Log2 Fold Change​	Clinical Significance​
PTHLH	Mammary development; bone metastasis mediator	-6.81	112x reduction; metastatic risk implication
AREG	EGFR ligand; ductal elongation signal	Significantly reduced	Estrogen growth signal muted
EREG	EGFR ligand; epithelial maintenance	Significantly reduced	Tissue maintenance signaling suppressed
WNT4	Progesterone-driven side-branching	-3.31	Proliferative cycling eliminated
RANKL	Stem cell regulation; side-branching	-4.47	Mammary expansion prevented
PGR	Progesterone receptor; ER activity marker	Significantly reduced	Confirms ER pathway is functionally blocked

Table 1: Key genes suppressed by testosterone in HR+ luminal breast cells (Phong et al., 2026 preprint)

The Protein-Level Proof: Progesterone Receptor as the Smoking Gun​

Gene expression data are powerful, but researchers needed confirmation that these transcriptomic changes translated into real biological effects. That confirmation came from immunofluorescence staining of breast tissue proteins.
The key finding centered on the progesterone receptor (PR). In breast biology, PR is the definitive downstream marker of estrogen receptor activity - it's only upregulated when estrogen receptor alpha (ER-alpha) is successfully activated. If PR protein is present, estrogen signaling is working. If PR disappears, the estrogen pathway is functionally blocked.
The results were striking. In an expanded cohort (11 control, 8 TRT), PR protein expression showed a significant decrease in the TRT group (p = 0.026). Meanwhile, ER-alpha protein itself actually trended slightly upward - a non-significant increase (p = 0.18). This dissociation is the smoking gun: the estrogen receptor is still physically present in the cells, but it's not doing its job. Testosterone has rendered it functionally inert. The receptors are there, but they can't activate their downstream targets.
For the ExcelMale community, this finding has an intuitive parallel. Many of you have heard Nelson discuss how estradiol levels on lab work don't always correlate with symptoms. A man can have an E2 of 50 pg/mL and feel fine, while another man at the same level develops nipple sensitivity. What this research shows is that the same dissociation operates at the tissue level - the presence of a hormone in the blood doesn't guarantee its activity in target tissues when a competing signal (in this case, testosterone) is strong enough.

Debunking the Aromatase Myth​

One of the most persistent fears in the TRT community - and in clinical practice more broadly - is the "aromatase concern": the idea that high testosterone levels will convert to excessive local estrogen through aromatase enzyme activity, potentially fueling breast tissue growth or even cancer. This fear drives many clinicians to prescribe aromatase inhibitors alongside TRT as a preventive measure.
The single-cell data directly contradict this narrative. Despite TRT subjects having serum testosterone levels between 234-758 ng/dL (well within the physiological male range) and measurable circulating estradiol, their breast tissue showed less estrogen signaling than controls - not more. The high abundance of testosterone didn't just counteract local estradiol. It overrode estrogen's transcriptional footprint entirely, keeping the mammary gland in a low-signaling state despite the availability of androgenic precursors for aromatization.
This is consistent with what the Cedars-Sinai team found in 2023. Their chromatin accessibility data showed that androgen receptor activation reprograms the regulatory landscape of breast cells in ways that physically block estrogen-responsive gene expression. It's not merely a competition for receptor binding - it's a fundamental rewiring of the cell's transcriptional machinery.
The practical takeaway for men on TRT? The automatic reflex to suppress estradiol with an aromatase inhibitor may be solving a problem that doesn't exist - at least in breast tissue. As Nelson has consistently advised on ExcelMale, treating a lab number rather than a symptom can backfire. Crashing estradiol with aggressive AI use carries well-documented risks: bone loss, joint pain, worsened lipid profiles, mood disturbances, and sexual dysfunction. These new data add another argument against routine AI use: the breast tissue is already handling testosterone-to-estrogen dynamics on its own.

What This Means for Men on TRT​

Let's bring this back to practical territory. If you're a man on testosterone replacement therapy, what do these molecular findings mean for you?
Gynecomastia risk in context. Gynecomastia on TRT is typically driven by a combination of genetics, excessive testosterone-to-estrogen conversion (often in men with high body fat), and individual receptor sensitivity. What this research confirms is that at physiological TRT doses, testosterone's dominant effect on breast tissue is suppressive, not stimulatory. The cells most vulnerable to estrogen-driven growth - HR+ luminal cells - are actually being quieted by testosterone, not activated. For most men at standard TRT doses, the testosterone-to-estradiol ratio naturally favors this protective effect.
The AI question. These data reinforce the growing consensus that aromatase inhibitors should not be prescribed routinely at TRT initiation. Nelson's long-standing protocol recommendation - wait 6-8 weeks, measure sensitive estradiol (LC-MS/MS), and intervene only if clear symptoms of excess develop - aligns well with what the molecular evidence shows. The breast isn't in danger from the estradiol being produced by normal aromatization of therapeutic testosterone doses.
Estradiol is your ally, not your enemy. As covered extensively in ExcelMale discussions, estradiol plays critical roles in bone density, cardiovascular protection, fat regulation, libido, and cognitive function in men. The Finkelstein study (NEJM 2013) demonstrated that fat accumulation and sexual dysfunction in hypogonadal men were primarily driven by estrogen deficiency. Suppressing this vital hormone to address a theoretical breast risk that the molecular data don't support is a losing trade.
Body composition matters. Adipose tissue is a major site of aromatase activity. Men carrying excess body fat will aromatize more testosterone to estradiol. But the solution isn't pharmacological suppression of estrogen - it's reducing the adipose tissue itself. Weight loss decreases aromatization naturally and brings a host of additional health benefits. The molecular data suggest that even when some aromatization is occurring, testosterone's direct effects on breast tissue remain protective.

Beyond TRT: Testosterone as a Breast Cancer Prevention Strategy​

The implications of this research extend well beyond the men's health space. For women - particularly postmenopausal women who are estrogen-deplete and at elevated risk for ER-positive breast cancer - testosterone therapy is attracting serious scientific attention as a potential protective intervention.
A 2021 study by Glaser and Dimitrakakis published in the European Journal of Breast Health followed 2,377 pre- and postmenopausal women treated with subcutaneous testosterone implants (either alone or combined with estradiol). Over 9,746 person-years of follow-up, the breast cancer incidence was 144 cases per 100,000 person-years - substantially lower than age-matched SEER population rates of 223 per 100,000. For women receiving testosterone combined with estradiol, the incidence dropped even further.
In September 2025, Wang and colleagues posted a major preprint demonstrating that testosterone therapy reduced the incidence of PIK3CA-mutant, ER-positive breast cancer by 81% in a mouse model (adjusted relative risk 0.19). Their human tissue analysis of 417 breast samples confirmed that testosterone promotes terminal duct lobular unit (TDLU) involution - the shrinking and simplification of breast glandular structures - which is itself associated with lower cancer risk.
And the Cedars-Sinai team, as noted by senior author Simon Knott, is now planning studies to evaluate what low-dose androgen therapy does to breast tissue in women at high risk for ER-positive breast cancer. The therapeutic hypothesis is straightforward: if testosterone can silence estrogen signaling in healthy breast tissue, it might prevent the estrogen-driven proliferation that initiates most breast cancers.
For ExcelMale readers, this broader context matters. Many of you have female partners navigating menopause, hormone therapy decisions, and breast cancer screening. Understanding that testosterone is emerging as a potential breast protector - not just a male hormone - adds depth to conversations about family health.

Limitations and What We Still Don't Know​

Strong as this evidence is, important caveats remain. Both the Phong et al. and Raths et al. studies used small cohorts (7-9 subjects per group). While single-cell technology provides extraordinary depth per subject, larger studies are needed to confirm these patterns across diverse populations, genetic backgrounds, and TRT durations.
The Phong et al. study is currently a preprint - it hasn't yet undergone formal peer review. That doesn't invalidate the findings, but it does mean the data should be interpreted with appropriate caution. The consistency with the peer-reviewed 2023 Cedars-Sinai paper strengthens the case, but replication in independent cohorts will be essential.
We also don't have long-term oncological outcome data from these cohorts. The molecular signatures strongly suggest a protective environment, but "reduced proliferative signaling" isn't the same as "proven cancer prevention." Longitudinal studies following individuals on TRT for decades will ultimately be needed to confirm whether these molecular changes translate into reduced cancer incidence.
It's also worth noting that the protective effect appears to be strongest against ER-positive breast cancer. A September 2025 preprint from Wang et al. found that testosterone therapy did not reduce the incidence of BRCA1-associated triple-negative breast cancer in mouse models. This makes biological sense - triple-negative tumors don't depend on estrogen receptor signaling, so blocking that pathway wouldn't help. Individuals with BRCA1/2 mutations likely need different surveillance and prevention strategies regardless of testosterone status.

Related ExcelMale Forum Discussions​

Explore these community discussions for additional insights:
Estradiol in Men on TRT: Why This 'Female Hormone' Is Your Most Underrated Metabolic Ally - Comprehensive overview of estradiol's essential roles in men, including why AI overuse is counterproductive.
Anastrozole for Men: The Complete Evidence-Based Guide for Testosterone Therapy - When aromatase inhibitors are justified, when they're not, and how to use them safely if needed.
Managing the Testosterone-to-Estradiol Ratio in Men on TRT - Practical guidance on the T:E ratio, what the research actually supports, and when to intervene.
High Estradiol in Men on TRT: What to Do - Nelson's video breakdown on estradiol management, including why clinics often overtreat.
Role of Estradiol (Estrogen) in Men and Its Management - The foundational ExcelMale thread with Nelson's AI dosing recommendations and the T:E ratio framework.
TRT Safety, Cancer Risk, and Healthy Ageing: Longevity Forum Panel - Expert panel discussion addressing TRT safety, cancer concerns, and genetic variability in androgen receptor sensitivity.
The FDA Announces Changes to HRT Product Labels - Coverage of the 2025-2026 FDA decision to remove black box warnings from hormone therapy products.
Estrogen Is Essential for Muscle Growth in Bodybuilders - Why aggressive estrogen suppression undermines muscle gains and overall health on TRT.
Treating Low Testosterone with Clomid, hCG and Aromatase Inhibitors: A Review - Clinical review of alternative TRT approaches and their effects on the estrogen-testosterone axis.
Testosterone/Estradiol Ratio Discussion - Community discussion on T:E ratio targets, long-term AI use concerns, and finding the right balance.

Key References​

1. Phong KT, Song S, Kim E, Conrad D, Gartner Z. Single cell RNA-sequencing reveals an association between testosterone treatment and reduced hormone signaling in the human mammary gland. bioRxiv. 2026 Jan 2. doi:10.64898/2025.12.31.697241
2. Raths F, Karimzadeh M, Ing N, et al. The molecular consequences of androgen activity in the human breast. Cell Genomics. 2023;3(3):100272. doi:10.1016/j.xgen.2023.100272
3. Wang L, et al. Masculinizing Testosterone Therapy Reduces the Incidence of PIK3CA-Mutant/ER+ Breast Cancer but Not BRCA1-Associated Triple-Negative Breast Cancer. medRxiv. 2025 Sep 15. doi:10.1101/2025.09.15.25335324
4. Glaser R, Dimitrakakis C. Breast cancer incidence reduction in women treated with subcutaneous testosterone: Testosterone Therapy and Breast Cancer Incidence Study. Eur J Breast Health. 2021;17(2):150-156. PMC8025725
5. Hickey TE, Robinson JLL, Carroll JS, Tilley WD. Minireview: The androgen receptor in breast tissues: Growth inhibitor, tumor suppressor, oncogene? Mol Endocrinol. 2012;26(8):1252-1267. PubMed:22745190
6. Berner AM, et al. Breast cancer in a transgender man. CA Cancer J Clin. 2025;75(5). doi:10.3322/caac.70021
7. Giovannelli P, Di Donato M, Galasso G, et al. The androgen receptor in breast cancer. Front Endocrinol. 2018;9:492. doi:10.3389/fendo.2018.00492
8. Finkelstein JS, Lee H, Burnett-Bowie SAM, et al. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med. 2013;369(11):1011-1022. doi:10.1056/NEJMoa1206168
9. Vasilev DJ, Kling JM, Carroll EF. Breast cancer risk and screening for transgender and gender-diverse individuals. Cleve Clin J Med. 2025;92(7):439-447. doi:10.3949/ccjm.92a.24088
10. Dimitrakakis C. Postmenopausal testosterone therapy and breast cancer risk. Maturitas. 2004;49(4):267-275. PubMed:15531122

Medical Disclaimer​

This article is provided for informational and educational purposes only and should not be construed as medical advice. The content is based on peer-reviewed research and clinical data, but individual health decisions should always be made in consultation with a qualified healthcare provider. Testosterone replacement therapy, aromatase inhibitor use, and breast cancer screening strategies should be tailored to each individual's clinical situation. Neither ExcelMale.com nor the author recommends starting, stopping, or changing any medication based solely on the information presented here.

About ExcelMale​

ExcelMale.com is the leading independent men's health forum with over 24,000 members and more than 20 years of archived discussions on testosterone replacement therapy, hormone optimization, sexual health, and evidence-based wellness. Founded by Nelson Vergel - a patient advocate, researcher, and author of Testosterone: A Man's Guide and Beyond Testosterone - ExcelMale bridges the gap between clinical research and real-world patient experience. The forum's evidence-first approach, primary source citations, and decades of community wisdom make it a trusted resource for both patients and healthcare providers navigating the complex landscape of men's hormone health.